If management knows a buyout is coming, then they're numbskulls to sell a major chunk of the company for $3 a share. And that CFO was an even bigger numbskull for checking out while all of his options were underwater.
Their powerhouse partner in that earthshaking collaboration announced in February, BIND Therapeutics, has gone chapter 11 and is about to be delisted. I understand that Jacob was planning on catching a ride to that Deutsche Bank Health Care Conference on the BIND corporate jet, which probably explains the cancellation.
Yes, Uncle Goofy - selling a major chunk of the company for $3 a share sure demonstrates "a position of strength". And it certainly confirms your belief that the company is worth $15 a share.
So I'm not dumb, clueless, or misinformed? Whew! That's the nicest compliment I've ever gotten here.
Tell me more about what you did in the war, Daddy.
You, on the other hand, are clinging to SGYP as it swirls ever closer to the drain. Motivated, of course, by the quaint belief that the company will be bought out at 12-15. Even though management appears to have just sold a massive chunk of it at 3. At the moment, IRWD constitutes less than 1% of my portfolio.
Buying into IRWD again just about where I left - 9.90's. Not a big position, but I may add to it if it shows signs of life.
All of the big thinkers who ponder the problem of shrinking working class income miss the most obvious solution of all: unions with real power. The Republicans have somehow convinced the working class that unions are the enemy and that there's something decadent about a manual worker making a living wage. Everyone bought the idea that the coddled American industrial worker had to be thrown into the ring with workers from third world countries. The days are gone when the Democratic party would not dare to displease the CIO. If nothing else, the Trump and Sanders campaigns call into question the orthodoxy that anything which brings down the cost of manufactures is essentially good. It's ironic that a oligarch and an old Trotskyite are voicing the complaints which should rightly be advanced by the union movement.
Yes, they cannily rejected that $12 offer from Shire and that $15 offer from Allergan and chose instead to sell 30m shares to some mysterious party @ $3. The source for this information is that same one you have cited repeatedly: Source.
Well, you convinced me. One of the few times I've found good info on these boards. Thanks.
Hawk has posted today that "the hopeometer level has definitely been raised". Now I understand how I have been consistently underrating this great company. I just checked my hopeometer and found that the batteries are dead!
Can't believe that you are questioning that unimpeachable source, "Source".
Actually, I sold out of all my IRWD at just under 10, which turned out to be too soon. I wasn't excited about their purchase of the rights to the gout drug (It pushed their profitability further out,) and the Phase Four (?) attack was the final straw. Even it was untrue, it injected too much risk into the stock. And yes, I did make a small profit on the sale since my average price was around 8.50. But my rule is to buy a stock under a fixed premise - in this case, the premise was that the company would be cash flow positive very soon. When something happens which calls my premise into question, I dump it.
Yes, I've been away on vacation. Did the Big Buyout happen yet? Was it for 15, as most here had surmised? Or did Shire lowball you at 12?
Back in just under 88, calculating that you are not only getting GILD cheap - you are also getting the company that they will eventually buy with all that cash for free.
Ps The plan that IRWD has followed in partnering with international drug companies in the development of Linzess is a virtual carbon copy of the plan that Medivation used in partnering with Astellas in developing Xtandi. That's worked out pretty well, I'd say,.
You say they sold the international rights for "a small royalty". They sold half the international rights - and the US rights - for substantial upfront payments and milestone payments. They get half the European and Mexican profits while their partners cover all of the developmental and marketing costs. In the case of the Chinese, Japanese, and other Asian markets, they get 50% of the profits, which eventually escalate to 55%. To this point, their partners have invested about $850 million in the development of Linzess.
Synergy is almost broke. They have about $80 million left and are burning through more than $25 million a quarter. They don't even have the cash to get to the end of the year, much less launch plecanatide, which will cost them at least an additional $200 milion in the initial year alone. Yeah, good luck, longs.
These Harvard guys are touchy. Maybe the Linzess rep parked in his space.